PTC Therapeutics | PTCT - Gross Profit On Sales


PTC Therapeutics reported $232.94M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amgen USD 6.89B 415M Dec/2025
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Cytokinetics USD 19.2M 1.44M Mar/2026
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Gilead Sciences USD 5.52B 791M Mar/2026
Incyte USD 1.17B 217.51M Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
Novartis USD 10.07B 184M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
TG Therapeutics USD 171.41M 16.98M Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026
Xencor USD 21M 22.61M Sep/2025